FDA Approves Novel Antibiotic for Treatment of Uncomplicated UTIs
Time to read: 01:21.GSK plc announced on the 25 March 2025, that the US FDA has approved Blujepa (gepotidacin), a first-in-class oral antibiotic, for treating uncomplicated urinary tract infections (uUTIs) in female adults and paediatric patients (=12 years, =40 kg).
Source: GSK Press Release, Drugs.com, FDA
Feature
Text
FDA Approves GSK’s Combination Penmenvy Vaccine to Protect Against Meningococcal Disease
Time to read: 01:02 The U.S. FDA has approved GSK’s new combination vaccine, Penmenvy, for meningococcal disease in individuals aged 10 to 25
Source: GSK Press Release, FDA Press Release
Text
FDA approves ZELSUVMI, thefirst novel drug for the treatment of ZELSUVMI, a treatment of Molluscum Contagiosum
The U.S. Food and Drug Administration (FDA) has approved ZELSUVMI™ (berdazimer gel, 10.3%), the first treatment for the highly contagious skin infection Molluscum contagious (molluscum).
Source: FDA, Clinicaltrials.gov, Ligand Pharmaceuticals
Text
Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged =18 Yearss
This phase 3 study evaluated the safety, tolerability, and immunogenicity of a 20-valent pneumococcal conjugate vaccine (PCV20).
Source: Clinical Infectious Diseases
Text
Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F (RSVPreF3) Candidate Vaccine in Older Adults: Phase 1/2 Randomized Clinical Trial
This study aimed to evaluate the safety and immunogenicity of vaccine formulations against respiratory syncytial virus (RSV) containing the stabilized prefusion conformation of RSV fusion protein (RSVPreF3).
Source: Journal of Infectious Diseases
Text
VALNEVA starts Phase I trial of VLA1553 for Chikungunya
Valneva has initiated a Phase I clinical trial to assess the safety and immunogenicity of its VLA1553 vaccine for Chikungunya, a viral disease transmitted by mosquitoes.
Source: Valneva Press Release, Clinical Trials Arena
Text
Infectious Diseases, Vaccines & Emergent Therapeutics Archive 2023
Novel Drugs and Emergent Therapeutics in the world of Infectious Diseases, Vaccines & Antimicrobials
Text
